Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q4 FY2019 Earnings Presentation
19 slides from Dr. Lal Pathlabs's earnings presentation, May 17, 2019
Slide 1: Cover letter to stock exchanges on results presentation
May 17, 2019 The National Stock Exchange of India Limited The Bombay Stock Exchange Limited Exchange Plaza Phiroze Jeejeeboy Towers Sandra Kurla Complex, Sandra (E) Dalal Street, Mumbai - 400051 Mumbai - 400001 Subject: Investors Presentation on Audited Financial Results (Standalone and Consolidated
Slide 2: Q4 & FY19 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q4 & FY19 Results Presentation May 17, 2019
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the “Company”) for use in presentat
Slide 4: Q4 FY19 Snapshot
Q4 FY19 Snapshot 3,011 mn ~10.6 mn 12.9% Samples Revenues INR Processed 729 mn ~4.32 mn 6.0% Patients Normalised INR Tested EBITDA 474 mn ~4,405 17.9% PAT INR Total Employees* *As on March 31, 2019 3
Slide 5: Table of Contents
Table of Contents 1 Overview of Dr. Lal PathLabs 2 Key Performance Highlights 3 Financial Table 4 Financial Highlights 5 Operating Highlights 6 Management Commentary 7 Outlook 8 Corporate Overview 9 Shareholding 10 Contact Us DISCLAIMER: This presentation may contain ‘forward-looking’ statements at
Slide 6: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs 200 clinical labs (including Established consumer National Reference Lab at healthcare brand in Delhi and Regional Reference diagnostic services lab at Kolkata), 2,569 Patient Service Centers (PSCs) and 6,426 Pick-up Points (PUPs)* Scalable model integrated Catalogue of
Slide 7: Key Performance Highlights
Key Performance Highlights Consistent growth in patient volumes for Q4 at 12.5% driving revenue growth for the quarter During Q4 FY19: • Revenues gained 12.9% YoY to Rs 3,011 million • Number of patients tested stood at 4.32 million in Q4 • Normalised EBITDA (after eliminating the impact of stock ba
Slide 8: Financial Table
Financial Table Particulars (Rs. mn) Q4 FY19 Q4 FY18 Growth % FY19 FY18 Growth % Revenue 3,011 2,668 12.9% 12,034 10,569 13.9% Expenditure 2,349 2,028 9,098 7,929 EBITDA 662 640 3.4% 2,936 2,640 11.2% Adj for stock based comp. & CSR Cost 67 48 196 143 Normalised operating EBITDA 729 688 6.0% 3,132 2
Slide 9: Financial Highlights
Financial Highlights Revenues All figures in Rs. mn Q4 saw 12.9% improvement in revenues at Rs. 3,011 million. This was the result of: 12,034 3,011 10,569 • Consistent momentum in volumes with 2,668 12.5 % growth • Gains in tests per patient from 2.3 to 2.5 Q4FY19 realisation per patient stood a
Slide 10: Financial Highlights
Financial Highlights PBT All figures in Rs. mn Q4 PBT was at Rs. 692 million vs. Rs. 3,006 620 million last year 692 2,613 620 Q4 PBT margin was at 23% from 23.2% last year FY 19 PBT came in at Rs. 3,006 million with margins of 25% Q4 FY18 Q4 FY19 FY18 FY19 PAT Q4 PAT came in at Rs. 474 mill
Slide 11: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs 189 193 200 2,569 6,426 2,153 5,624 1,759 5,021 FY17 FY18 FY19 FY17 FY18 FY19 FY17 FY18 FY19 No. of patients (mn) No. of samples (mn) 17.6 41.8 15.2 34.7 13.3 29.3 FY17 FY18 FY19 FY17 FY18 FY19 10
Slide 12: Management Commentary
Management Commentary Commenting on the results announcement, Dr. Arvind Lal - Chairman and Managing Director said; "I am glad with the continuous advancement Dr. Lal PathLabs brand which stands for providing high quality and accurate services to patients at affordable prices. Robust volume and samp
Slide 13: Outlook
Outlook Robust operating model best-positioned to capitalize on growth trends in diagnostic services -one of the fastest-growing segments of the Indian healthcare industry Will leverage established position of a strong consumer healthcare brand in diagnostic services Initiatives to improve brand con
Slide 14: Corporate Overview
Corporate Overview • DLPL Strategy for future growth • Experienced Management team 13
Slide 15: DLPL Strategy for future growth
DLPL Strategy for future growth 1) Strengthen Existing 2) Expansion in Offering Operations 3) Expand management of hospital based and clinical 4) Geographic expansion laboratories 14
Slide 16: DLPL Strategy for future growth
DLPL Strategy for future growth 1 Strengthen Existing Operations Boosting quality & Improving Grow basic Online initiatives Investment in reliability turnaround times radiology practice and data analytics branding standards for testing 2 Expansion in Offering Improve breadth Preventive Chronic & Lif
Slide 17: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Chairman and Managing Director Whole-time Director and Chief Whole-time Director Executive Officer Ved Prakash Goel Bharath Uppiliappan Shankha Banerjee Chief Financial Officer CEO India Business Chief Growth O
Slide 18: Shareholding as of 31st March, 2019
Shareholding as of 31st March, 2019 56.9% 8.4% Promoter and Promoter Mutual Group Funds* 17.7% 17.0% FII Others *Mutual Funds includes Alternate Investment Funds as well 17
Slide 19: Contact us
Contact us About Dr Lal PathLabs Limited (DLPL) For further information please contact: Dr Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. Ved Goel / Rajat Kalra It has an integrated nationwide network, where patients Dr. Lal PathLabs Limited and heal